S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
NASDAQ:TYRA

Tyra Biosciences (TYRA) Stock Price, News & Analysis

$14.89
-0.18 (-1.19%)
(As of 04/12/2024 ET)
Today's Range
$14.62
$15.14
50-Day Range
$14.89
$20.00
52-Week Range
$10.38
$20.67
Volume
79,037 shs
Average Volume
175,048 shs
Market Capitalization
$782.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Tyra Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
47.8% Upside
$22.00 Price Target
Short Interest
Bearish
14.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Tyra Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$298,165 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.89) to ($2.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.31 out of 5 stars

Medical Sector

763rd out of 923 stocks

Pharmaceutical Preparations Industry

362nd out of 428 stocks

TYRA stock logo

About Tyra Biosciences Stock (NASDAQ:TYRA)

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

TYRA Stock Price History

TYRA Stock News Headlines

My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
TYRA Mar 2024 20.000 call
TYRA Mar 2024 20.000 put
Wedbush stays Outperform on Tyra Biosciences after pipeline updates
See More Headlines
Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
4/13/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TYRA
Fax
N/A
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.00
High Stock Price Target
$28.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+47.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-69,130,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.74 per share

Miscellaneous

Free Float
42,857,000
Market Cap
$782.04 million
Optionable
Optionable
Beta
1.12
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Todd Harris Ph.D. (Age 45)
    Co-Founder, President, CEO, Secretary, Treasurer & Director
    Comp: $903.33k
  • Mr. Daniel Bensen (Age 48)
    Co-Founder & COO
    Comp: $630.8k
  • Mr. Ali D. Fawaz J.D.
    General Counsel & Secretary
  • Mr. Alan Fuhrman (Age 67)
    Chief Financial Officer
  • Dr. Robert L. Hudkins Ph.D. (Age 68)
    Chief Technology Officer
  • Dr. Ronald V. Swanson Ph.D. (Age 60)
    Chief Scientific Officer
    Comp: $536.19k
  • Ms. Sarah Honig
    Vice President of Corporate Development & Strategy
  • Dr. Hiroomi Tada M.D. (Age 59)
    Ph.D., Chief Medical Officer
    Comp: $519.65k
  • Dr. Piyush R. Patel Ph.D. (Age 58)
    Chief Development Officer
  • Amy Conrad
    Investor Contact

TYRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Tyra Biosciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TYRA shares.
View TYRA analyst ratings
or view top-rated stocks.

What is Tyra Biosciences' stock price target for 2024?

3 Wall Street analysts have issued 1 year price objectives for Tyra Biosciences' shares. Their TYRA share price targets range from $15.00 to $28.00. On average, they predict the company's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 47.8% from the stock's current price.
View analysts price targets for TYRA
or view top-rated stocks among Wall Street analysts.

How have TYRA shares performed in 2024?

Tyra Biosciences' stock was trading at $13.85 at the start of the year. Since then, TYRA shares have increased by 7.5% and is now trading at $14.89.
View the best growth stocks for 2024 here
.

When is Tyra Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our TYRA earnings forecast
.

How were Tyra Biosciences' earnings last quarter?

Tyra Biosciences, Inc. (NASDAQ:TYRA) issued its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.33.

What ETF holds Tyra Biosciences' stock?

Range Cancer Therapeutics ETF holds 7,883 shares of TYRA stock, representing 1.17% of its portfolio.

When did Tyra Biosciences IPO?

Tyra Biosciences (TYRA) raised $100 million in an initial public offering on Wednesday, September 15th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share.

How do I buy shares of Tyra Biosciences?

Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TYRA) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners